Harold E. “Barry” Selick, Ph.D., Chairman, Independent Director, Vice Chancellor for Business Development, Innovation and Partnerships at University of California, San Francisco

Portrait

Dr. Selick has served on our board of directors since February 2009. Dr. Selick is Vice Chancellor for Business Development, Innovation and Partnerships at University of California San Francisco. He also serves as Chairman of Molecular Templates effective August 2017. He served as CEO of Threshold Pharmaceuticals from June 2002 to April 2017, which recently merged with Molecular Templates. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL), he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab). Dr. Selick serves as Lead Director of PDL, a public company, and serves as Chairman of the board of directors of Catalyst Biosciences, a privately held drug discovery and development company. Dr. Selick received his B.A. in Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Bryan Giraudo, Independent Director, Chief Financial Officer, Gossamer Bio

Portrait

Mr. Giraudo has recently joined us as a member of our board of directors. He has served as Chief Financial Officer of Gossamer Bio since May 2018. From August 2009 to May 2018, Mr. Giraudo served as Senior Managing Director at Leerink Partners, where he was responsible for Leerink’s Western North America and Asia life sciences investment banking practice. While at Leerink, he executed more than 150 initial public offerings, follow-on, convertible and structured debt and equity transactions, as well as product and company buy-side, sell-side and corporate collaboration strategic advisory assignments for biotechnology and pharmaceutical clients. From July 1997 to July 2009, Mr. Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Mr. Giraudo received his B.A. from Georgetown University.

Sarah Noonberg, M.D., Ph.D., Independent Director, Chief Medical Officer, Maze Therapeutics

Portrait

Dr. Noonberg has served as a member of our board of directors since December 2017 and is currently Chief Medical Officer at Maze Therapeutics. Prior to joining Maze she was Chief Medical Officer at Nohla Therapeutics leading development of a universal cell therapy for hematologic malignancies. Other executive leadership roles have included Chief Medical Officer of Prothena Biosciences where she led programs in hematology and immunotherapy, Head of Global Clinical Development at BioMarin where she advanced a broad portfolio of development programs for rare genetically-defined diseases, and Senior Vice President at Medivation where she led translational and early development activities as well as late stage development of enzalutamide (XTANDI™) for advanced prostate cancer. Dr. Noonberg also serves on the Board of Directors at Neoluekin Therapeutics. Dr. Noonberg earned her M.D. at the University of California, San Francisco and her Ph.D. in Bioengineering at the University of California, Berkeley. Dr. Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital.

Sarah O’Dowd, Independent Director

Portrait

Ms. O’Dowd has recently joined us in August 2020 as an independent member of our board of directors. From September 2008 to March 2020 she served as Senior Vice President, Chief Legal Officer and Secretary of Lam Research Corporation, an S&P 500 company. She also served as its VP of Global Human Resources from March 2009 to May 2012. From February 2007 to August 2008 she served as Vice President and General Counsel of FibroGen, Inc. She has advised multiple public and private life science companies on M&A, strategic transactions and governance, including ALZA Corporation, Jazz Pharmaceuticals, Corcept Therapeutics, Adeza BioMedical, and Threshold Pharmaceuticals. She also serves on the board of directors of Ichor Corporation. She received a J.D. and an M.A. in Communications from Stanford University and an A.B. in Mathematics from Immaculata College.

Dinesh V. Patel, Ph.D., Director, President & CEO, Protagonist Therapeutics

Portrait

Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

William D. Waddill, Independent Director

Portrait

Mr. Waddill has served as a member of our board of directors since July 2016. From April 2014 to December 2016, Mr. Waddill served as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences, Inc. From October 2007 to March 2014, Mr. Waddill served as Senior Vice President and Chief Financial Officer at OncoMed Pharmaceuticals, Inc., a biopharmaceutical company. From October 2006 to September 2007, Mr. Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. From February 2000 to September 2006, Mr. Waddill served as a Principal at Square One Finance, a financial consulting business. From December 1996 to February 2000, Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at Pricewaterhouse Coopers LLP and Deloitte LLP.

Lewis T. “Rusty” Williams, M.D., Ph.D., Director, Co-Founder, Chairman and CEO of Walking Fish Therapeutics

Portrait

Dr. Williams, Co-Founder, Chairman and CEO of Walking Fish Therapeutics and a Venture Partner at Quan Capital, has served as a member of our board of directors since June 2017. He founded Five Prime Therapeutics, Inc. in December 2001 and served as Executive Chairman of the Board until 2012 and as President and Chief Executive Officer from August 2011 to December 2017. He is currently a member of the Five Prime Board of Directors. Previously, Dr. Williams spent seven years at Chiron Corporation, now Novartis Vaccines and Diagnostics, Inc., most recently as Chief Scientific Officer. He also served on Chiron’s board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the boards of directors of COR Therapeutics, Inc. and Beckman Coulter, Inc., each of which was a public company. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.